

Special Issue

Drug and Gene Delivery Nanoformulations against Cancer Hallmarks

Message from the Guest Editors

In 2000, Hanahan and Weinberg proposed a list of six advantageous and complementary biological capabilities that enable tumour growth, survival, and metastatic dissemination, the so-called hallmarks of cancer, with the aim to reduce the intricacy of cancer biology. Such list included sustained proliferative signalling, insensitivity to growth suppressors, cell death resistance, replicative immortality, sustained angiogenesis, and tissue invasion and metastasis. Years later, they added typical cancer features to the list, such as altered energy metabolism and immune surveillance evasion. The definition of cancer hallmarks has encouraged the development of specific therapeutic approaches directed to their inhibition, which is expected to slow down/prevent cancer growth.

This Special Issue aims to bring together recently developed therapeutic strategies based on drug/gene nanocarriers targeted to obstacle tumour progression acting on one or multiple hallmarks. We invite reviews or articles on all aspects of “Drug and Gene Delivery Nanoformulations against Cancer Hallmarks”.

Guest Editors

Dr. Eduardo Ruiz-Hernandez

Dr. Amelia Ultimo

Dr. Luiza C. S. Erthal

Deadline for manuscript submissions

closed (20 May 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/45924

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).